Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

168.16
-0.6500-0.39%
Post-market: 168.08-0.0800-0.05%19:57 EDT
Volume:11.12M
Turnover:1.86B
Market Cap:43.39B
PE:-11.83
High:168.51
Open:168.23
Low:165.19
Close:168.81
52wk High:176.60
52wk Low:141.05
Shares:258.02M
Float Shares:258.02M
Volume Ratio:1.37
T/O Rate:4.31%
Dividend:2.55
Dividend Rate:1.52%
EPS(TTM):-14.2170
EPS(LYR):-14.2170
ROE:-9.22%
ROA:1.03%
PB:1.26
PE(LYR):-11.83

Loading ...

Abbvie - Full-Year 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $13.76-$13.96 - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Gaap and Adj Earnings Include $216 Mln Bought Ipr&D and Milestones Expense - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie Inc. Fy2026 Shr View $14.02

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $3.73-$3.77 - SEC Filing

THOMSON REUTERS
·
Oct 06

Genmab, AbbVie Say New Drug Combo Helps Lymphoma Patients Stay Cancer-Free Longer

MT Newswires Live
·
Oct 06

Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL

TIPRANKS
·
Oct 06

AbbVie Blood Cancer Drug Combo Cuts Risk of Progression or Death in Late-Stage Study

Reuters
·
Oct 06

Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study

TIPRANKS
·
Oct 06

Genmab Says Phase 3 Epcore DLBCL-2 Trial Shows Epcoritamab Plus R-CHOP Cuts Progression or Death Risk 51% in Newly Diagnosed DLBCL

Reuters
·
Oct 06

Genmab - Phase 3 Trial Shows 51% Reduction in Risk of Progression or Death in Dlbcl

THOMSON REUTERS
·
Oct 06

Genmab: Safety Profile of Epcoritamab When Administered in Combination with Standard of Care R-Chop was Generally Well Tolerated

THOMSON REUTERS
·
Oct 06

Genmab and Abbvie Announce Epcoritamab in Combination with R-Chop Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
Oct 06

Eli Lilly Stock (LLY) Gains on Regulatory Win for Experimental Cancer Drug

TIPRANKS
·
Oct 06

Sector Update: Healthcare Stocks Rise Monday Afternoon

MT Newswires Live
·
Oct 06

Exchange-Traded Funds Rise, US Equities Higher After Midday

MT Newswires Live
·
Oct 06

Emeis Executes Share Buyback as Mission-Driven Care Group Expands Role in Vulnerable Healthcare

TIPRANKS
·
Oct 06

Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Pacira Pharmaceuticals (PCRX)

TIPRANKS
·
Oct 06

Lilly Expands Oncology Footprint with FDA Win for Pancreatic Cancer Drug

Dow Jones
·
Oct 05

UnitedHealth Group Faces Texas AG Investigation Over Coverage Practices

MT Newswires Live
·
Oct 05

Analysts’ Top Healthcare Picks: GE Healthcare Technologies Inc (GEHC), Harrow Health (HROW)

TIPRANKS
·
Oct 05